Brent Greetham has been appointed as the new chief financial officer (CFO) at Surgical Innovations Group, with effect from 24 February.

He will replace the firm’s current CFO, Chris Martin, who is leaving the business to pursue another opportunity. Martin will step down from the board on 14 February.

Brent brings over 25 years of experience in the life sciences, having held senior finance leadership roles in various life science, biotech and manufacturing organisations.

His most recent role was as senior finance director for the discovery division at Charles River Laboratories, having previously served in finance leadership roles at Thermo Fisher Scientific, Gilead Sciences and Mission Therapeutics.

The appointment comes after Surgical Innovations Group reported that its full-year revenues will be "broadly in line with market expectations".

Its adjusted EBITDA is set to be "slightly ahead" of expectations, while its cost management and restructuring efforts have contributed to a "profitable second half", compared to the first half of the year.

Chief executive officer at Surgical Innovations Group, David Marsh, said: "After a challenging start to 2024, I am pleased with the turnaround delivered in H2 24, following stringent cost controls, and the strong platform this has given us for growth. I look forward to updating shareholders further at our preliminary results in March.

"I would like to thank Martin for all his efforts and support during his time as CFO and look forward to working with Greetham, and benefiting from his experience in the life sciences sector, as we strive to deliver continued growth to the group."

---